Skip to main content
SpringerLink
Log in

Heparin und Hirudin — Unterschiede in der pharmakologischen Wirkung

  • Chapter
Thromboembolie-Prophylaxe in der Inneren und operativen Medizin

  • 18 Accesses

Zusammenfassung

Während Heparin seit langem in der Prophylaxe und Therapie von venösen und arteriellen Thrombosen etabliert ist, wird Hirudin, nachdem seine gentechnische Herstellung vor einigen Jahren gelang, für diese Indikationen derzeit klinisch erst erprobt. Da die diesbezügliche Zulassung von Hirudin voraussichtlich jedoch bald erteilt werden wird, ist es klinisch relevant, die Wirkprofile beider Substanzen vergleichend zu betrachten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC (1976) Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound anti-thrombin III and by gel filtration. Thromb Res 9:575–583.

    Article  PubMed  CAS  Google Scholar 

  2. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderstrom G (1979) Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X effect of heparin neutralization in plasma. Thromb Res 15:531–541.

    Article  PubMed  CAS  Google Scholar 

  3. Bagdy D, Barabas E, Graf L (1973) Large scale preparation of hirudin. Thromb Res 2:229–232.

    Article  CAS  Google Scholar 

  4. Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J (1981) Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 370:644–649.

    Article  PubMed  CAS  Google Scholar 

  5. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G (1983) Structure activity relationships in heparin: a synthetic pentasaccharide with high affinity for anti-thrombin III and eliciting high anti factor Xa activity. Biochem Biophys Res Commun 116:492–499.

    Article  PubMed  CAS  Google Scholar 

  6. Consensus conference: Prevention of deep venous thrombosis and pulmonary embolism (1986) JAMA 256:744–749

    Article  Google Scholar 

  7. Crafoord C (1937) Preliminary report on postoperative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 79: 407–426.

    Google Scholar 

  8. European Consensus Statement (1992) Prevention of venous thromboembolism. Internat Angiology 11:151–159.

    Google Scholar 

  9. Franz F (1904) Über die Blutgerinnung aufhebenden Bestandteil des medizinischen Blutegels. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmacol 49:342–357.

    Article  Google Scholar 

  10. Greinacher A, Eichler P (1995) Die Heparin-assoziierte Thrombozytopenie — Immunologische Aspekte. Hämostaseologie 14:117–121.

    Google Scholar 

  11. Griffith MJ (1983) Heparin-catalyzed inhibitor/protease reactions: Kinetic evidence for a common mechanism of action of heparin. Proc Natl Acad Sci USA 80:5460–5464.

    Article  PubMed  CAS  Google Scholar 

  12. Haas S, Haas P (1996) Niedermolekulare Heparine-Die Anwendung in Klinik und Praxis. ZETT-Verlag, Steinen.

    Google Scholar 

  13. Haycraft JB (1894) Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Gerinnbarkeit des Bluts. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmakol 18209–217

    Google Scholar 

  14. Holmer E, Kurachi K, Söderström G, (1981) The molecular weight dependency of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, IXa, Xla, Xlla and kallikrein by antithrombin. Biochem J 193:395–400.

    PubMed  CAS  Google Scholar 

  15. Howell W, Holt E (1918) Two new factors on blood coagulation: Heparin and proantithrombin. Am J Physiol 48:328–334.

    Google Scholar 

  16. Jacobi Y (1904) Über Hirudin. Dtsch Med Wschr 30:1786–1787.

    Google Scholar 

  17. Jutisz M., Charbonnel-Berault A, Marindoli G (1963) Purification de l’hirudine. Bull Coc Chim Biol 45:55–67.

    CAS  Google Scholar 

  18. Markwardt F (1956) Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften 43:111–112.

    Article  CAS  Google Scholar 

  19. Markwardt F (1956) Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmacol 229:389–399.

    Article  CAS  Google Scholar 

  20. Markwardt F (1956) Untersuchungen über Hirudin. Naturwissenschaften 42: 537–538.

    Article  Google Scholar 

  21. Markwardt F (1957) Bestimmung des Thrombins durch Titration mit Hirudin. Arch Pharmazie 290:280–284.

    Article  CAS  Google Scholar 

  22. Markwardt F (1957) Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem 308:147–156.

    Article  PubMed  CAS  Google Scholar 

  23. Markwardt F (1958) Die quantitative Bestimmung des Prothrombins durch Titration mit Hirudin. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmacol 232:487–498.

    Article  CAS  Google Scholar 

  24. Markwardt F (1958) Hirudin, der blutgerinnungshemmende Wirkstoff des medizinischen Blutegels. Blut 4:161–170.

    Article  Google Scholar 

  25. Markwardt F (1958) Versuche zur pharmakologischen Charakterisierung des Hirudins. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmacol 234:516–529.

    CAS  Google Scholar 

  26. Markwardt F (1959) Der Hirudintoleranztest. Klin Wchenschr 37:1142–1143.

    Article  CAS  Google Scholar 

  27. Markwardt F (1959) Über den Einfluß des Hirudins auf die Thrombenbildung. Naunyn Schmiedeberg’s Arch Exp Pathol Pharmacol 236:286.

    CAS  Google Scholar 

  28. Markwardt F (1970) Hirudin as an inhibitor of thrombin. In: Colowick SP, Kaplan NO (eds) Methods in enzymology, vol. XIX: Proteolytic enzymes. Academic Press, New York, pp 924–932.

    Google Scholar 

  29. Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P (1982) Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 47:226–229.

    PubMed  CAS  Google Scholar 

  30. Markwardt F, Schäfer G, Töpfer H, Walsmann P (1967) Die Isolierung des Hirudins aus medizinischen Blutegeln. Pharmazie 22:239–241.

    CAS  Google Scholar 

  31. Markwardt F, Walsmann P (1958) Die Reaktion zwischen Hirudin und Thrombin. Hoppe Seylers Z Physiol Chem 312:85–98.

    Article  PubMed  CAS  Google Scholar 

  32. Markwardt F, Walsmann P (1967) Reindarstellung Analyse des Thrombin-Inhibitors Hirudin. Hoppe Seylers Z Physiol Che 348:1381–1386.

    Article  CAS  Google Scholar 

  33. Markwardt F, Wentzel G (1961) Die Anwendung der Prothrombinbestimmung mit Hirudin zur Überwachung der Behandlung mit Dicumarolderivaten. Blut 7,3740.

    Article  Google Scholar 

  34. Mathiasson SE, Lindblad B, Stjernquist U, Bergqvist D (1995) The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 25:203–211.

    Google Scholar 

  35. McLean J (1916) The thromboplastic actin of cephalin. Am J Physiol 41:250–257.

    Google Scholar 

  36. Murray DWG, Jaques LB, Perrett TS, Best CH (1937) Heparin and the thrombosis of veins following injury. Surgery 2:163–187.

    CAS  Google Scholar 

  37. Nowak G, Bucha E (1996) Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 2:197–202.

    Article  Google Scholar 

  38. Petersen TE, Roberts HR, Sotrup-Jensen L, Magnusson S (1976) Primary structure of hirudin, a thrombin-specific inhibitor. In: Peeters H (ed) Proteins of the Biologic Fluids. Pergamon Press, Oxford, pp 145–149.

    Google Scholar 

  39. Petitou M, Duchaussoy P, Ledermann I, Choay J, Jacquinet JC, Sinay P, Tarri G (1987) Synthesis of heparin fragments a methyl-pentoside with high affinity for antithrombin III. Carbohydr Res 67:67–75.

    Article  Google Scholar 

  40. Rosenberg RD, Damus PS (1973) The purification and mechanisms of action of human antithrombin-heparin cofactor. J Biol Chem 248:6490–6505.

    PubMed  CAS  Google Scholar 

  41. Sandset M, Abildgaard U, Larsen ML (1988) Heparin induces release of extrinsic coagulation pathway inhibitor. Thromb Res 50:803–813.

    Article  PubMed  CAS  Google Scholar 

  42. Walsmann P, Markwardt F (1985) On the isolation of the thrombin inhibitor hirudin. Thromb Res 40:563–570.

    Article  PubMed  CAS  Google Scholar 

  43. Warn-Cramer BJ, Almus FE, Rapaport SL (1989) Studies of the factor xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Hemost 61:101–105.

    CAS  Google Scholar 

Download references

Authors
  1. S. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wiiliam-Harvey-Klinik, Abteilung Innere Medizin, Am Kaiserberg 6, D-61231, Bad Nauheim, Germany

    Viola Hach-Wunderle

  2. Institut für Experimentelle Chirurgie, Technische Universität München, Ismaniger Str. 22, D-81675, München, Germany

    Sylvia Haas

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haas, S. (1997). Heparin und Hirudin — Unterschiede in der pharmakologischen Wirkung. In: Hach-Wunderle, V., Haas, S. (eds) Thromboembolie-Prophylaxe in der Inneren und operativen Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60569-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60569-7_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61773-0

  • Online ISBN: 978-3-642-60569-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation